You are currently browsing the archives for July 2018.
Displaying 31 - 34 of 34 entries.

Axolotls two EHR systems receive ONC-ATCB certification Axolotl Corp.

Axolotl’s two EHR systems receive ONC-ATCB certification Axolotl Corp www.cialisinnederland.com . Announced that two of its digital wellness record systems – Axolotl EHR, edition 7 and Elysium EMR Lite – have obtained Workplace of the National Coordinator for Wellness IT Authorized Examining and Qualification Body 2011/2012 certifications relative to Eligible Provider certification requirements used by the U.S. Division of Health insurance and Human Providers . ‘Complete EHR qualification for Axolotl EHR edition 7 and modular qualification for Elysium EMR Lite displays our dedication to giving health info exchanges a variety of pre-integrated ambulatory EHR systems they can offer with their physician members to improve collaboration across patient treatment groups and throughout their communities,’ stated Glenn Keet, president of Axolotl.

CartiHeal secures $5M in venture funding CartiHeal.

The capability to regenerate hyaline cartilage, rather than ‘hyaline-like cartilage, in a single stage procedure, without the use of exogenous cells or growth factors, is considered the Holy Grail in cartilage restoration. The Agili-CTM can be CE marked and the business happens to be running post-marketing clinical research at leading centers in European countries and Israel. Related StoriesImproved outcomes yielded from new ChIP-seq protocolLiposomal sizing and the Coulter principle: an interview with Professor Melvin E. KlegermanLinkam phases used in the Wolfson Bioimaging Facility at the University of Bristol as part of the endocytic sorting research of Dr Paul VerkadeThere are around 1.2 million cartilage repair methods performed world-wide annually, according to BioMedGPS.

Baxter enters definitive contract to acquire Prism Baxter International Inc.

The transaction is likely to close in the next quarter of 2011, at the mercy of customary closing circumstances and expiration of the waiting around period beneath the Hart-Scott-Rodino Antitrust Improvements Action. This transaction isn’t likely to have a materials effect on Baxter’s 2011 economic outcomes. The NEXTERONE premixed IV formulations had been recently accepted by the FDA in two ready-to-make use of dosage forms: 150 mg in a 100 mL flexible container for speedy 10-minute loading infusion and 360 mg in a 200 mL versatile container for subsequent loading and maintenance infusions. These ready-to-use formats need no admixing, removing potential medicine errors connected with compounding. Furthermore, NEXTERONE could be stored at space heat range during its two 12 months shelf life and ties in automated dispensing cupboards and crash carts, placing the merchandise in patient treatment areas ready for make use of during acute, time delicate and life-threatening situations.

Patients in every treatment groupings continued using NSAIDs through the entire trial.

Array BioPharma announces excellent results from ARRY-797 Phase 2 trial on osteoarthritis Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled Phase 2 medical trial in 157 osteoarthritis patients experiencing moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs . Patients in every treatment groupings continued using NSAIDs through the entire trial. The investigational compound, ARRY-797, is definitely a novel, oral, selective p38 inhibitor with a mechanism of action unique from that of currently approved pain medications.